Pathology opinions received: Grade Gr... - Prostate Cancer N...

Prostate Cancer Network

4,941 members3,076 posts

Pathology opinions received: Grade Group 2 vs Grade Group 1

climb4blue profile image
5 Replies

My next step is to meet with experts in all therapies that have been known to work best for men with my diagnosis of PNI and potential %pattern 4. Opinions and suggestion welcome.

1st opinion GS 3+4=7, NCCN Grade Group 2, favorable-intermediate risk group

highest %cancer: 50% %pattern 4: 8%

2nd opinion GS 3+3=6, NCCN Grade Group 1, low risk group

TNM stage: T1c, N0, M0

PSA 5.97

PSAD 0.143

PELVIC MRI showed no signs of EPE, no lymph or bladder invasion, normal bones, and other pelvic organs normal.

Written by
climb4blue profile image
climb4blue
To view profiles and participate in discussions please or .
Read more about...
5 Replies
Tall_Allen profile image
Tall_Allen

Decipher?

climb4blue profile image
climb4blue in reply to Tall_Allen

Here is the story on getting the Decipher test instead of Oncotype.

The doctor, who did my biopsy and who thought I could be a good candidate for AS if genomic testing results came back favorable, said he does not use Decipher. He felt strongly that Oncotype was the most appropriate test and Decipher was not appropriate at all for my situation.

He did not read those studies that I provided but said they were not in alignment with papers he has read in the past.

I explained that as a patient, that I needed a genomic test that I could rely upon for decision making and that I won't be able to do that with Oncotype because of those studies. I asked that he not order Oncotype because I did not feel it was informative. He told me I would have to find someone else to order Decipher.

At first, I thought I was sort of in a bind, because I really had no alternative doctor to order Decipher.

Then I thought, I should speak with my first pathologist (Dr. Ayala), to gain more insight in risk stratification. Perhaps I am really not a candidate for AS because of additional risks having PNI. Moreover, I still did not have my % pattern 4 except from deriving it myself from the report, adenocarcinoma (mm)/total sample (mm), which came to 8%. I didn't know for sure if was 5% or 45% because I didn't know if the report I was using was providing amounts intended for this type of computation.

I spoke with my first pathologist about the PNI, and the % pattern 4. He felt PNI needed treatment, and the fidelity percentage of the % pattern 4 was between 5% - 10% and that I should not be using the report to compute it.

When the 2nd opinion (Dr. Epstein) came in at 3+3, so there is that, no % pattern 4.

I figure either could be right about % pattern 4, but PNI was confirmed.

Tall_Allen profile image
Tall_Allen in reply to climb4blue

Epstein is the gold standard. You can see why now.

Does your urologist make money from getting Oncotype for patients? At any rate - any Uro who refuses to order Decipher at patient's request deserves to be fired. There are lots of urologists.

climb4blue profile image
climb4blue in reply to Tall_Allen

I did leave this part out in my prior explanation: When told I would have to go elsewhere for Decipher, I ended our patient-doctor relationship explicitly, and informed him to cancel all future appointments between us.

Tall_Allen profile image
Tall_Allen in reply to climb4blue

Good man!

You may also like...

Opinions requested – biopsy pathology report

PRAD4 lesion 4. highest percent of cancer in any core 5. % pattern 4 Q1: Is it normal for pathology...

Pathology Question: Percentage of Gleason grade per core?

with carcinoma is 40% The percentage of Gleason grade 4 and/or 5 is 25% For the Gleason 4+3 Core...

Pathology changed with 2nd opinion - your thoughts appreciated.

I just received my 2nd opinion report of the pathology slides back from Johns Hopkins - performed by

Update after RALP ---- Need advice

Gleason score 4+3 (70% pattern 4 with cribriform) Grade Group: upgraded from 2 to 3 EPE:...

Prostate cancer what to do.

as an option. I was giving a risk factor of favorable intermediate risk of a 14 core sample all were